Table 3.
Probiotics | Functional carrier | Experimental model | Principle of action | Treatment time | Reference |
---|---|---|---|---|---|
Lactobacillus delbrueckii Lb100 & Lactococcus lactis AM1 |
Yogurt | SHRs | ACE-Inhibitory | 4 weeks | (Glazunova et al., 2022) |
Lactobacillus helveticus H9 | Fermented milk | SHRs | ACE-Inhibitory | 6-12h | (Chen et al., 2014) |
Bifidobacterium bifidum MF20/5 | Fermented milk | \ | ACE-Inhibitory | \ | (Gonzalez-Gonzalez et al., 2013) |
Lactiplantibacillus plantarum NK181 & Lactobacillus delbrueckii KU200171 | Yogurt | \ | Antioxidant and ACE-Inhibitory | \ | (Kim et al., 2021) |
Lactiplantibacillus plantarum SR37-3 & Lactiplantibacillus plantarum SR61-2 |
Fermented milk | SHRs | L-NAME inhibiting | 4 weeks | (Yuan et al., 2022) |
Lactobacillus acidophilus BCRC14065 & Lactobacillus delbrueckii subsp. lactis BCRC12256 & Lactobacillus gasseri BCRC14619 |
Yogurt | SHRs | Activating compensatory IGF-IR/PI3K/Akt survival pathways | 8 weeks | (Lin et al., 2013a) |
Lactobacillus casei Shirota | Fermented milk | Clinical Experiment | \ | 3 times a week | (Aoyagi et al., 2017). |
Lactobacillus
helveticus CM4 |
The tablets containing powdered fermented milk | Clinical Experiment | ACE-Inhibitory | 4 weeks | (Aihara et al., 2005) |
Lactobacillus acidophilus NCDC-15 | Fermented camel milk | \ | ACE-Inhibitory | \ | (Solanki et al., 2022) |
Lactobacillus casei
ATCC7469 |
Fermented milk | \ | ACE-Inhibitory | \ | (Elkhtab et al., 2017) |
Lactobacillus plantarum C4 | Fermented milk | \ | ACE-Inhibitory | \ | (Moreno-Montoro et al., 2017) |
Lactobacillus bulgaricus LB6 | Fermented milk | \ | ACE-Inhibitory | \ | (Shu et al., 2019) |
Lactiplantibacillus plantarum Y7 | Fermented pickle | \ | \ | \ | (Kim et al., 2022) |
Kefir | Fermentation of milk by kefir grains | SHRs | Improving the structural and functional integrity of the intestinal wall and preventing neuroinflammation within the heart’s regulatory nucleus | 9 weeks | (De Almeida Silva et al., 2020) |
Kefir | Fermented milk | Male Wistar rats | ACE-Inhibitory | 7 weeks | (Amorim et al., 2019) |
Lactobacillus helveticus R0389 &
Lactocaseibacillus rhamnosus R0011 |
Fermented milk | Cell model | ACE-Inhibitory& Inducing the production of NO |
\ | (Adams et al., 2020) |
Lactobacillus bulgaricus
& Lactobacillus helveticus MB2-1 & Lactobacillus plantarum B1-6 & Lactobacillus plantarum 70810 |
Navy bean milk | \ | ACE-Inhibitory | \ | (Rui et al., 2015) |
Lactobacillus acidophilus BCRC14065 & Lactobacillus delbrueckii subsp. lactis BCRC12256 & Lactobacillus gasseri BCRC14619 |
Yogurt | SHRs | Inhibiting inflammatory pathways | \ | (Lin et al., 2013b) |
Lactobacillus casei SY13 | Yogurt | \ | ACE-Inhibitory | \ | (Obaroakpo et al., 2019) |
Lactobacillus casei BGP93 & Streptococcus thermophilus TA-40 |
Dairy beverages | \ | ACE-Inhibitory | \ | (Pereira et al., 2019) |
Lactobacillus sp. FTDC2113 & Lactobacillus acidophilus FTDC8033 & Lactobacillus acidophilus ATCC4356 & Lactobacillus casei ATCC393 & Bifidobacterium FTDC8943 & Bifidobacterium longum FTDC8643 |
Soymilk | \ | ACE-Inhibitory | \ | (Yeo and Liong, 2010) |
Lactobacillus plantarum DSM15313 | Blueberries fermented | SHRs | \ | 4 weeks | (Ahrén et al., 2015) |
Clostridium butyricum pMTL007-GLP-1 | Engineered probiotics | SHRs | \ | \ | (Wang et al., 2023) |
The table summarizes the probiotic strains, functional carriers of probiotics, experimental models, mechanisms of action, and duration of treatment. The “/” indicates that the relevant content is not mentioned in the reference.